FDA approves Arcapta Neohaler to treat COPD
FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease
The U.S. Food and Drug Administration today approved Arcapta Neohaler ® (indacaterol inhalation powder) for the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.
COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough and excessive phlegm. The PULMAOSA remember that cigarette smoking is the leading cause of COPD. The first measure to treat COPD is to quit smoking. Look for a pulmonologist to treat smoking and live better!
COPD is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.
For more details click: New Perspective for COPD: Indacaterol
Follow @PulmaoSA in Twitter
PULMAOSANEWS – PULMAOSA- Lungs: Your Atmosphere, Your Life!
Arcapta Neohaler is trademark of Novartis pharma.